Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases

(2017) Kamran A. Ahmed et al.   JOURNAL OF NEURO-ONCOLOGY

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy

(2016) K. A. Ahmed et al.   ANNALS OF ONCOLOGY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

(2016) E. Liniker et al.   OncoImmunology

Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment

(2015) Ana P. Kiess et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery

(2015) Andrew Yaeh et al.   JOURNAL OF NEURO-ONCOLOGY

Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials

(2015) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Response assessment criteria for brain metastases: proposal from the RANO group

(2015) Nancy U Lin et al.   LANCET ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment

(2015) J. V. Cohen et al.   Cancer Immunology Research

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

(2015) Ravi A Chandra et al.   OncoImmunology

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

(2015) Jonathan D. Schoenfeld et al.   Journal for ImmunoTherapy of Cancer

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery

(2014) Karim Tazi et al.   Cancer Medicine

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

(2012) Jonathan P. S. Knisely et al.   JOURNAL OF NEUROSURGERY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases

(2011) Paul W. Sperduto et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline

(2009) Mark E. Linskey et al.   JOURNAL OF NEURO-ONCOLOGY